Home » Stocks » NYMX

Nymox Pharmaceutical Corporation (NYMX)

Stock Price: $1.79 USD -0.12 (-6.28%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $1.78 -0.01 (-0.56%) May 7, 4:53 PM
Market Cap 140.89M
Revenue (ttm) 5,000
Net Income (ttm) -11.74M
Shares Out 78.71M
EPS (ttm) -0.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $1.79
Previous Close $1.91
Change ($) -0.12
Change (%) -6.28%
Day's Open 1.88
Day's Range 1.68 - 1.90
Day's Volume 410,765
52-Week Range 1.68 - 4.79

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

HASBROUCK HEIGHTS, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) today announced it has entered into a definitive agreement with institutional ...

1 week ago - GlobeNewsWire

HASBROUCK HEIGHTS, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide the latest update on the Company's regulatory filing preparation activit...

1 month ago - GlobeNewsWire

HASBROUCK HEIGHTS, N.J., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current update on the regulatory filing status for Fexapotide Triflutat...

5 months ago - GlobeNewsWire

HASBROUCK HEIGHTS, N.J., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced it has entered into definitive agreements with institutional and accredited i...

8 months ago - GlobeNewsWire

HASBROUCK HEIGHTS, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report current updates on the Company's most important ongoing developments. Th...

9 months ago - GlobeNewsWire

HASBROUCK HEIGHTS, N.J., June 19, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is very pleased to report that key steps in its regulatory submission preparations have been ...

10 months ago - GlobeNewsWire

HASBROUCK HEIGHTS, N.J., April 21, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce the recent allowances of 4 new different US and international patents...

1 year ago - GlobeNewsWire

HASBROUCK HEIGHTS, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce that a new peer review report was published today in the World Journal...

1 year ago - GlobeNewsWire

HASBROUCK HEIGHTS, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce the new appointment of Russell I. Thomson PhD, FRSC to the position of...

1 year ago - GlobeNewsWire

HASBROUCK HEIGHTS, N.J., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current January 2020 update on several important corporate activities...

1 year ago - GlobeNewsWire

HASBROUCK HEIGHTS, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report a new peer review research report has been published on experimental stu...

1 year ago - GlobeNewsWire

HASBROUCK HEIGHTS, N.J., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report very positive fundamental news, that the Company has received several ne...

1 year ago - GlobeNewsWire

Insiders only buy their stocks for one reason -- to make money. Here are 6 stocks to buy based on the recent insider buying.

Other stocks mentioned: CCL, GEF, HOFT, KR, PLAY
1 year ago - InvestorPlace

NYMX has been targeted by shorts like Richard Pearson, and longs have supported a completely opposite value statement.

1 year ago - Seeking Alpha

About NYMX

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAler... [Read more...]

Industry
Biotechnology
IPO Date
Dec 1, 1997
Stock Exchange
NASDAQ
Ticker Symbol
NYMX
Full Company Profile

Financial Performance

In 2020, NYMX's revenue was $5,000, a decrease of -95.69% compared to the previous year's $116,000. Losses were -$11.74 million, -10.82% less than in 2019.

Financial Statements